At EAN 2022, Cristina Tassorelli, Professor of Neurology, University of Pavia, Italy, discussed how treatment goals are evolving and improving due to an increasing number of targeted therapies for migraine. In the past, the benchmark of efficacy was 50% reduction in number of migraine days per month and alternative drugs were offered if this goal was not met. With current, migraine-specific, medication, migraine days can be reduced by 75% per month for at least some patients, with a wider treatment choice if this goal is not met.